Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C95214
http://purl.obolibrary.org/obo/NCIT_C95214
Preferred Name

Ozarelix
Definitions
A highly modified, fourth generation linear decapeptide with gonadotropin-releasing hormone (GnRH or LHRH) antagonizing properties. Ozarelix competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with hormonally dependent disease states such as hormone-dependent prostate cancer.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A highly modified, fourth generation linear decapeptide with gonadotropin-releasing hormone (GnRH or LHRH) antagonizing properties. Ozarelix competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with hormonally dependent disease states such as hormone-dependent prostate cancer.
prefLabel
Ozarelix
label
Ozarelix
PDQ_Closed_Trial_Search_ID
690937
code
C95214
prefixIRI
NCIT:C95214
in_subset
Preferred_Name
Ozarelix
FDA_UNII_Code
Q1IF8M2YL3
Contributing_Source
FDA
Maps_To
Ozarelix
CAS_Registry
295350-45-7
NCI_Drug_Dictionary_ID
690937
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
690937
Semantic_Type
Amino Acid, Peptide, or Protein
Pharmacologic Substance
UMLS_CUI
C2987000
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display